Success Stories: Strengthening Public Health Systems Against Future Epidemics: NIW Approval Granted

Client’s Testimonial:

“Overall, I am very satisfied with the support right from my case assessment through to filing my I-140. The team has been excellent at providing me with guidance on all the documentation needed. I got frequent and gentle nudges to keep the momentum on collecting all the required documentation. My recommendation letters were drafted clearly and in detail, requiring almost no further revision from my recommenders.”

On January 27^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Care and Support Advisor in the Field of Public Health Medicine (Approval Notice).

General Field: Public Health Medicine

Position at the Time of Case Filing: Senior Care and Support Advisor

Country of Origin: Uganda

Country of Residence at the Time of Filing: South Africa

Approval Notice Date: January 27^th, 2025

Processing Time: 9 months, 26 days

Case Summary:

An EB-2 NIW (National Interest Waiver) petition prepared by NAILG was recently approved for a public health medicine expert from Uganda. At the time of filing, the client was conducting important research on infectious disease epidemics, focusing on their associations and causes in order to inform public health policies, strengthen preparedness, and refine interventions for epidemic control. His proposed endeavor is of clear, substantial merit and national importance, given the ongoing threat of infectious and vector-borne diseases worldwide.

Research with Substantial Merit and National Importance
NAILG demonstrated that our client’s work is directly tied to safeguarding public health and mitigating the socioeconomic impacts of disease outbreaks. His research addresses urgent needs posed by vector-borne diseases and re-emerging conditions once thought to be eradicated, thereby ensuring health systems remain prepared for evolving threats. By advancing evidence-based prevention and management strategies, his work improves epidemic control efforts and supports resilient public health systems. This research is indispensable to the United States, providing tools and policies that optimize national resilience against illness and protect both lives and economic stability.

Evidence of Accomplishments
The petition highlighted our client’s contributions to the field of public health medicine, including:

6 peer-reviewed journal articles, with 1 first-authored publication.
1 conference abstract documenting his findings.
60 citations to his published work, underscoring its influence in the research community.
Completion of at least 2 peer reviews for respected journals.
Independent testimonial evidence, including: “ [Client]’s research has considerably advanced the efforts of the public health medicine research community and provided the information and methods necessary to enhance the safety and effectiveness of VMMC programs.”

These accomplishments demonstrate both his recognition as a trusted contributor in public health medicine and his proven ability to advance his proposed endeavor in the United States.

NIW Approval and Outlook
USCIS granted approval after recognizing the strong record of accomplishments presented and the national importance of his proposed research. With NAILG’s support, the petition effectively demonstrated how his expertise advances epidemic preparedness and control in the United States. This approval allows him to continue his vital work in infectious disease research, generating insights that will improve public health strategies and strengthen the nation’s ability to respond to future epidemics.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.